<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02926183</url>
  </required_header>
  <id_info>
    <org_study_id>1881</org_study_id>
    <nct_id>NCT02926183</nct_id>
  </id_info>
  <brief_title>Study of NAC of GA Therapy for Patients With BRPC</brief_title>
  <official_title>Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wakayama Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wakayama Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international&#xD;
      oncology meeting and represents a new standard regimen in the treatment of metastatic&#xD;
      pancreatic cancer. Therefore, it was decided to consider the balance of safety and efficacy&#xD;
      on survival time as a preoperative chemotherapy, the investigators use the NAC-GA regimen&#xD;
      includes only two cycles (three times weekly and one week rest) of GA regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international&#xD;
      oncology meeting and represents a new standard regimen in the treatment of metastatic&#xD;
      pancreatic cancer. GA is one of the high response rate treatment regimen, the investigators&#xD;
      considered as a promising treatment as neoadjuvant chemotherapy. On the other hand,&#xD;
      incidences of grade 3 or 4 neutropenia, febrile neutropenia and peripheral neuropathy were&#xD;
      significantly higher in the g group compared with gemcitabine group. Therefore, it was&#xD;
      decided to consider the balance of safety and efficacy on survival time as a preoperative&#xD;
      chemotherapy, the investigators use the NAC-GA regimen includes only two cycles (three times&#xD;
      weekly and one week rest) of GEMABR regimen. The investigators also evaluate Recurrence free&#xD;
      survival from the first day of protocol therapy, safety of the protocol therapy(Adverse&#xD;
      effect), morbidity based on Clavien Dindo classification of more than Grade 3, response rate,&#xD;
      preoperative/postoperative tumor marker (CA19-9, CEA), rate of mornalization, reduction rate&#xD;
      of SUVmax value on PET-CT (limited only for PET-CT available institutions), chemotherapeutic&#xD;
      effect grade based on Evans classification, resection rate, R0 resection rate, surgical data&#xD;
      (operative time, blood loss, transfusion, postoperative hospital day), the overall morbidity&#xD;
      rates (Reoperation, rate of re-admission, mortality), number of patient rate in postoperative&#xD;
      adjuvant therapy (entry rate, completion rate), dose intensity for borderline resectable&#xD;
      pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival time from the first day of protocol therapy</measure>
    <time_frame>Up to 60 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence free survival from the first day of protocol therapy</measure>
    <time_frame>Up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effect</measure>
    <time_frame>Up to 30 weeks</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity based on Clavien Dindo classification of more than Grade3</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapeutic effect grade based on Evans classification</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative blood loss</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall morbidity rates based on Clavien Dindo classification</measure>
    <time_frame>Up to 50 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patient rate in postoperative adjuvant therapy</measure>
    <time_frame>Up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose intensity</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel: Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel</intervention_name>
    <description>Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.</description>
    <arm_group_label>Gemcitabine plus nab-paclitaxel</arm_group_label>
    <other_name>NAC-GA for BRPC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically diagnosed as pancreatic adenocarcinoma, and consistent&#xD;
             with NCCN guideline (Version 2. 2016) borderline resectable-arterial, borderline&#xD;
             resectable-venous&#xD;
&#xD;
          2. Case with measurable lesion&#xD;
&#xD;
          3. First line treatment&#xD;
&#xD;
          4. PS (ECOG) 0-1&#xD;
&#xD;
          5. &gt;= 20 years old and &lt;80 years old&#xD;
&#xD;
          6. The following criteria must be satisfied in laboratory tests within 14 days of&#xD;
             registration&#xD;
&#xD;
               -  WBC count&lt;=12,000/mm3&#xD;
&#xD;
               -  Neutrophil count&gt;=1,500/mm3&#xD;
&#xD;
               -  Hb &gt;= 9.0g/dl&#xD;
&#xD;
               -  Plt &gt;= 100,000/mm3&#xD;
&#xD;
               -  T.Bil &lt;2.0mg/dl (&lt;3=.0mg/dl in biliary drainage case)&#xD;
&#xD;
               -  Serum Cr&lt;=upper limits of normal (ULN)&#xD;
&#xD;
               -  AST, ALT &lt;= 2.5xULN&#xD;
&#xD;
          7. Written informed consent to participate in this study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe drug hypersensitivity&#xD;
&#xD;
          2. Multiple primary cancers within 5 years&#xD;
&#xD;
          3. Severe infection&#xD;
&#xD;
          4. With grade2 or more severe peripheral neuropathy&#xD;
&#xD;
          5. Interstitial pneumonia or pulmonary fibrosis&#xD;
&#xD;
          6. With uncontrollable pleural effusion or ascites&#xD;
&#xD;
          7. With uncontrollable diabetes mellitus&#xD;
&#xD;
          8. With uncontrollable heart failure, angina, hypertension, arrhythmia&#xD;
&#xD;
          9. With severe neurological/psychological symptoms&#xD;
&#xD;
         10. With watery diarrhea&#xD;
&#xD;
         11. Pregnant or lactating women or women with unknown or suspected pregnancy&#xD;
&#xD;
         12. Inappropriate patients for entry on this study in the judgement of the investigator&#xD;
&#xD;
         13. Diagnosed as Resectable/Unresectable pancreatic carcinoma on NCCN guideline (Version&#xD;
             2.2016)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ken-ichi Okada, M.D., Ph.D.</last_name>
    <phone>+81-73-441-0613</phone>
    <email>okada@wakayama-med.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hirosaki University</name>
      <address>
        <city>Hirosaki</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Keinosuke Ishido, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kobe University</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hirochika Toyama, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jiro Fujimoto, M.D., PhD.</last_name>
    </contact>
    <investigator>
      <last_name>Kazuhiro Suzumura, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nara Medical University</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masayuki Sho, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sohei Satoi, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinki University</name>
      <address>
        <city>Sayama</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ippei Matsumoto, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka University</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hidetoshi Eguchi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka Medical University</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mitsuhiro Asakuma, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shiga Medical University</name>
      <address>
        <city>Ōtsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masaji Tani, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chiba University</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hideyuki Yoshitomi, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gifu University</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kazuhiro Yoshida, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hiroshima University</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yoshiaki Murakami, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kumamoto University</name>
      <address>
        <city>Kumamoto city</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daisuke Hashimoto, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hisashi Ikoma, M.D., PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyoto University</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toshihiko Masui, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya University</name>
      <address>
        <city>Nagoya, Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tsutomu Fujii, M.D., PhD.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka City University</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ryosuke Amano, M.D., PhD.</last_name>
    </contact>
    <investigator>
      <last_name>Ryosuke Amano, M.D., PhD.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Department of Surgery, Wakayama Medical University, School of Medicine, 811-1 Kimiidera</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken-ichi Okada, M.D., Ph.D.</last_name>
      <phone>+81-73-441-0613</phone>
      <email>okada@wakayama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroki Yamaue, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2016</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wakayama Medical University</investigator_affiliation>
    <investigator_full_name>Hiroki Yamaue</investigator_full_name>
    <investigator_title>NAC-GA investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

